Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements - Additional Information (Details)

v3.21.1
Fair Value Measurements - Additional Information (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Dec. 31, 2020
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Estimated fair value of equity securities $ 30,955 $ 41,644
Unrealized loss on equity securities 10,689  
Vaxcyte, Inc. | Vaxcyte Common Stock    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Estimated fair value of equity securities 31,000  
Unrealized loss on equity securities $ 10,700  
Equity Securities | Vaxcyte, Inc. | Vaxcyte Common Stock    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Number of shares held 1,567,324